Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)
Condition: Cholangiocarcinoma, Gall Bladder Carcinoma
Study Type: Interventional
Clinical Trials Identifier NCT 8-digits: NCT02170090
Sponsor: Universitätsklinikum Hamburg-Eppendorf
Phase: Phase 3
Eligibility:
- Age: minimum 18 Years maximum N/A
- Gender: All
Eligibility Criteria:
- for patients to be included in the radiotherapy substudy:
- R1 (microscopic positive margin)
- no previous radiotherapy to abdomen
View trial on ClinicalTrials.gov
